uniQure Target of Unusually Large Options Trading (NASDAQ:QURE)

uniQure (NASDAQ:QUREGet Free Report) saw some unusual options trading activity on Tuesday. Stock investors purchased 6,252 call options on the company. This is an increase of 589% compared to the typical volume of 908 call options.

Institutional Trading of uniQure

Large investors have recently made changes to their positions in the stock. Raymond James & Associates lifted its holdings in uniQure by 6.4% in the 4th quarter. Raymond James & Associates now owns 52,224 shares of the biotechnology company’s stock valued at $354,000 after purchasing an additional 3,145 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of uniQure by 58.5% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 3,664 shares during the last quarter. Harbor Capital Advisors Inc. lifted its stake in shares of uniQure by 21.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 30,883 shares of the biotechnology company’s stock valued at $209,000 after buying an additional 5,389 shares during the period. Pale Fire Capital SE boosted its position in uniQure by 9.2% during the fourth quarter. Pale Fire Capital SE now owns 65,600 shares of the biotechnology company’s stock worth $444,000 after acquiring an additional 5,500 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in uniQure during the fourth quarter worth approximately $86,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Stock Up 76.5 %

QURE stock opened at $6.67 on Wednesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 9.39 and a quick ratio of 9.27. uniQure has a 12 month low of $3.73 and a 12 month high of $11.61. The firm has a market capitalization of $323.83 million, a PE ratio of -1.05 and a beta of 0.97. The company’s 50 day simple moving average is $4.76 and its 200-day simple moving average is $5.31.

uniQure (NASDAQ:QUREGet Free Report) last announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) EPS for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.05). The company had revenue of $8.49 million for the quarter, compared to analyst estimates of $2.58 million. uniQure had a negative net margin of 1,562.22% and a negative return on equity of 121.60%. Equities analysts expect that uniQure will post -4.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

QURE has been the topic of several research analyst reports. Mizuho decreased their price target on uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 8th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of uniQure in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $23.00.

Read Our Latest Analysis on QURE

About uniQure

(Get Free Report)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

Further Reading

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.